Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Mol Ther. 2000 Oct;2(5):601-6.

Technology evaluation: AAV factor IX gene therapy, Avigen Inc.

Author information

  • 1Department of Biochemistry, Royal Holloway College, University of London, Egham, Surrey, TW20 OEX, UK. s.fabb@rhbnc.ac.uk

Abstract

Avigen has developed a recombinant adeno-associated viral vector expressing human blood-coagulation Factor IX (F.IX) for the potential treatment of hemophilia B. In a phase I clinical trial being conducted at The Children's Hospital of Philadelphia and Stanford University Medical Center, the vector, AAV-CMV-hF.IX (Coagulin-B), was injected at a low dose into three patients with severe hemophilia B. No evidence of toxicity, germline transmission of vector sequences, or formation of inhibitory antibodies against F.IX was observed, and in two of the three patients there was an indication of a modest clinical response.

PMID:
11249763
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk